Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

Malignant melanoma as a target malignancy for the study of the anti-metastatic properties of the heparins

Maraveyas, Anthony, Johnson, Miriam J., Xiao, Yu Pei and Noble, Simon Ian Robert 2010. Malignant melanoma as a target malignancy for the study of the anti-metastatic properties of the heparins. Cancer and Metastasis Reviews 29 (4) , pp. 777-784. 10.1007/s10555-010-9263-y

Full text not available from this repository.

Abstract

The outlook for metastatic melanoma to the brain is dismal. New therapeutic avenues are therefore needed. The anti-metastatic mechanisms that may underpin the effects of low molecular weight heparins (LMWHs) in in vitro and preclinical melanoma models warrant translating to a clinical setting. This review outlines a rationale that supports our proposal that metastatic melanoma to the brain is a clinical setting in which to study the anti-metastatic potential of LMWHs. Prevention or delay of brain metastases in melanoma is a clinically relevant and measurable target. Studies to explore the effect of anticoagulants on cancer survival are underway in other malignancies such as lung, pancreas, ovary, breast, and stomach cancer. However, no study to our knowledge has a methodology that could produce clinical evidence in support of a mechanism for whatever benefit may be seen. The setting we propose would allow translation of the molecular knowledge of the metastatic pathways mediated by platelets and the selectins—all potential targets of heparin—in a “time to appearance” of brain metastases endpoint. Since brain metastases are so common and they have a singularly adverse impact on survival, the “biological neuroprotection” model we propose in metastatic melanoma could provide the translational evidence to support the benefit of LMWHs in melanoma. More significantly, this would open the door to a wider “anti-metastatic” approach that could have much greater impact in patients with minimal disease being treated in adjuvant settings for the more common malignancies such as breast and colon cancer.

Item Type: Article
Date Type: Publication
Status: Published
Schools: Medicine
Subjects: R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)
Uncontrolled Keywords: low molecular weight heparins, metastatic melanoma, selectin, anti-metastatic
Publisher: Springer
ISSN: 0167-7659
Last Modified: 04 Jun 2017 03:35
URI: http://orca-mwe.cf.ac.uk/id/eprint/23267

Citation Data

Cited 18 times in Google Scholar. View in Google Scholar

Cited 13 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item Edit Item